Our Pipeline

Deargen streamlines the initial R&D stage of new drug development with A.I. Each of Deargen's programs focuses on diseases with high medical demands, such as anticancer drugs, cardiovascular and metabolic diseases, neurological diseases, and immune diseases.

Oncology

Neurology

Rare Disease

Dermatology

Crop Protectant

4D Program

The 4D (Deargen-Driven Drug Development) program is a new drug development pipeline led by Deargen from the discovery of Hit substances. Using A.I, we develop optimal new drug candidates through the iterative process of prediction, synthesis, validation, and re-learning.

Target ID
Hit Discovery
Lead Optimization
Preclinical

DGD-201 | DLBCL

DGP-101 | Immuno-oncology

DGP-108 | NSCLC

DGP-113 | TNBC

DGP-114 | Ovarian Cancer

Co-Developed Program

Deargen is developing new drugs through various cooperation with domestic and overseas drug developers.

Target ID
Hit Discovery
Lead Optimization
Preclinical

DGC610 | Rare Disease

DGC803 | Herbicide

DGC804 | Fungicide

DGC805 | Herbicide

DGC601 | Neurology

DGC810 | Dermatology

Service Agreement

DGC811 | Dermatology

Service Agreement